9592 related articles for article (PubMed ID: 1300766)
1. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Glinkina LS; Bruvere RZh
Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
[TBL] [Abstract][Full Text] [Related]
2. [The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir].
Glinkina LS; Bruvere RZh; Venskus DR; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):540-7. PubMed ID: 1300752
[TBL] [Abstract][Full Text] [Related]
3. [The humoral immunity indices of patients with malignant skin melanoma using the viral immunomodulator rigvir].
Glinkina LS; Heisele OG; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):534-40. PubMed ID: 1300751
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
5. [Changes in certain immunological parameters in patients with malignant skin melanoma].
Lukács L; Bárdosi L; Somos Z; Kocsis B
Orv Hetil; 1985 Apr; 126(14):819-26. PubMed ID: 3873050
[No Abstract] [Full Text] [Related]
6. [Nonspecific cell-mediated immunity in gastric cancer patients - with special reference to immuno-reactivity of the regional lymph node and preoperative immunotherapy].
Takeshita M
Nihon Geka Gakkai Zasshi; 1983 Aug; 84(8):679-91. PubMed ID: 6610095
[TBL] [Abstract][Full Text] [Related]
7. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
8. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
9. Immunologic function in humans before and after hyperthermia and chemotherapy for disseminated malignancy.
DeHoratius RJ; Hosea JM; Van Epps DE; Reed WP; Edwards WS; Williams RC
J Natl Cancer Inst; 1977 Apr; 58(4):905-11. PubMed ID: 300437
[TBL] [Abstract][Full Text] [Related]
10. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
[TBL] [Abstract][Full Text] [Related]
11. [Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
[No Abstract] [Full Text] [Related]
12. [A comparison of the morphofunctional characteristics of the peripheral blood lymphocytes and the immune status of patients with malignant melanoma of the skin].
Naleskina LA; Ganina KP; Labunets IF; Grinevich IuA; Abramenko VA
Tsitol Genet; 1996; 30(5):16-22. PubMed ID: 9026985
[TBL] [Abstract][Full Text] [Related]
13. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
Doniņa S; Strēle I; Proboka G; Auziņš J; Alberts P; Jonsson B; Venskus D; Muceniece A
Melanoma Res; 2015 Oct; 25(5):421-6. PubMed ID: 26193376
[TBL] [Abstract][Full Text] [Related]
14. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
15. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
16. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
17. [Mononuclear cell reactions in the combined treatment of patients with a cutaneous melanoblastoma of the lower extremities].
Turkina NV; Freĭdlin IS; Chetvertakova LV; Levin AO; Andrianov IG
Vopr Onkol; 1984; 30(7):45-50. PubMed ID: 6464401
[TBL] [Abstract][Full Text] [Related]
18. An immunological aspect of melanoma and its potential application in adjuvant therapy.
Elias EG; Tomazic VJ
J Surg Oncol; 1991 Dec; 48(4):220-3. PubMed ID: 1745045
[TBL] [Abstract][Full Text] [Related]
19. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]